Aortic Stenosis Management in Patients With Acute Hip Fracture
- PMID: 38939644
- PMCID: PMC11198465
- DOI: 10.1016/j.jacadv.2024.100912
Aortic Stenosis Management in Patients With Acute Hip Fracture
Abstract
The treatment of severe aortic stenosis (SAS) has evolved rapidly with the advent of minimally invasive structural heart interventions. Transcatheter aortic valve replacement has allowed patients to undergo definitive SAS treatment achieving faster recovery rates compared to valve surgery. Not infrequently, patients are admitted/diagnosed with SAS after a fall associated with a hip fracture (HFx). While urgent orthopedic surgery is key to reduce disability and mortality, untreated SAS increases the perioperative risk and precludes physical recovery. There is no consensus on what the best strategy is either hip correction under hemodynamic monitoring followed by valve replacement or preoperative balloon aortic valvuloplasty to allow HFx surgery followed by valve replacement. However, preoperative minimalist transcatheter aortic valve replacement may represent an attractive strategy for selected patients. We provide a management pathway that emphasizes an early multidisciplinary approach to optimize time for hip surgery to improve orthopedic and cardiovascular outcomes in patients presenting with HFx-SAS.
Keywords: HOS; SAVR; TAVR; aortic stenosis; balloon aortic valvuloplasty; hip fracture; hip fracture surgery; management; minimalist transcatheter aortic valve replacement; non cardiac surgery; protocol; transcatheter aortic valve replacement; treatment algorithm.
© 2024 The Authors.
Conflict of interest statement
Funding support was received from the Section of Cardiology, John W. Deming Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA. Dr George is a consultant (honoraria) for Zimmer Biomet, Atricure, Neosurgery, Neptune Medical, Abbvie, Johnson & Johnson, Boston Scientific, Edwards Lifesciences, Medtronic, Help-TheraX, 3ive, Encompass, Summus Medical, and Abbott SJM; is on the advisory boards for Edwards Surgical, Medtronic Surgical, Medtronic Structural Mitral & Tricuspid, Trisol Medical, Abbvie, Johnson & Johnson, Foldax Medical, Zimmer Biomet, Neosurgery, Abbvie, Boston Scientific, and Summus Medical; has equity in Valcare Medical, Durvena, CardioMech, Vdyne, MitreMedical, and MITRx; and has received institutional funding to Columbia University: Edwards Lifesciences, Medtronic, Abbott Vascular, Boston Scientific, JenaValve. Dr Latib is on the advisory board for Medtronic, Abbott Vascular, Boston Scientific, Edwards Lifesciences, Shifamed, and Philips. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Figures







References
-
- Omsland T.K., Magnus J.H. Forecasting the burden of future postmenopausal hip fractures. Osteoporos Int. 2014;25:2493–2496. - PubMed
-
- Loggers S.A.I., Van Lieshout E.M.M., Joosse P., et al. Prognosis of nonoperative treatment in elderly patients with a hip fracture: a systematic review and meta-analysis. Injury. 2020;51:2407–2413. - PubMed
-
- Osnabrugge R.L., Mylotte D., Head S.J., et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol. 2013;62:1002–1012. - PubMed
Publication types
LinkOut - more resources
Full Text Sources